• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性阻塞性肺疾病患者的炎症和免疫特征:与第1秒用力呼气容积可逆性的关系

Inflammatory and immunological profiles in patients with COPD: relationship with FEV 1 reversibility.

作者信息

Queiroz Cleriston Farias, Lemos Antonio Carlos Moreira, Bastos Maria de Lourdes Santana, Neves Margarida Célia Lima Costa, Camelier Aquiles Assunção, Carvalho Natália Barbosa, Carvalho Edgar Marcelino de

机构信息

Serviço de Pneumologia, Ambulatório Magalhães Neto, Complexo Hospitalar Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador (BA) Brasil.

Universidade do Estado da Bahia, Salvador (BA) Brasil.

出版信息

J Bras Pneumol. 2016 Jul-Aug;42(4):241-247. doi: 10.1590/S1806-37562015000000122.

DOI:10.1590/S1806-37562015000000122
PMID:27832230
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5063439/
Abstract

OBJECTIVE

: To determine whether COPD severity correlates with sputum cell counts, atopy, and asthma.

METHODS

: This was a cross-sectional study involving 37 patients with COPD and 22 healthy subjects with normal lung function (controls). Sputum cell counts were determined by microscopy after centrifugation of samples. Skin prick tests were performed, and serum cytokines were determined by ELISA.

RESULTS

: Patients were stratified by bronchodilator response: a non-reversible airflow limitation (nonRAL) group comprised 24 patients showing no significant post-bronchodilator change in FEV1; and a partially reversible airflow limitation (partialRAL) group comprised 13 patients showing FEV1 reversibility (post-bronchodilator FEV1 increase ≥ 12%). The proportion of eosinophils in sputum was higher in the partialRAL group than in the nonRAL group (p < 0.01), and there was an inverse correlation between the proportion of eosinophils and FEV1 (p < 0.05). However, none of the patients had a history of asthma and skin prick test results did not differ between the two groups. In the patient sputum samples, neutrophils predominated. Serum levels of TNF, IL-6, IL-8, and RANTES (CCL5) were higher in patients than in controls (p < 0.001) but did not differ between the two patient groups.

CONCLUSIONS

: COPD patients with partial FEV1 reversibility appear to have higher sputum eosinophil counts and greater airway hyperresponsiveness than do those with no FEV1 reversibility. However, we found that COPD severity did not correlate with atopy or with the cytokine profile.

OBJETIVO

: Determinar se a gravidade da DPOC se correlaciona com a contagem de células no escarro, atopia e asma.

MÉTODOS:: Estudo transversal com 37 pacientes com DPOC e 22 indivíduos saudáveis com função pulmonar normal (controles). As contagens de células no escarro foram determinadas por microscopia após a centrifugação das amostras. Foram realizados testes cutâneos de puntura, e as citocinas séricas foram determinadas por ELISA.

RESULTADOS

: Os pacientes foram estratificados pela resposta ao broncodilatador: o grupo de limitação ao fluxo aéreo não reversível (LFAnr) envolveu 24 pacientes sem alteração significativa do VEF1 pós-broncodilatador, e o grupo de limitação ao fluxo aéreo parcialmente reversível (LFApr) envolveu 13 pacientes com reversibilidade do VEF1 (aumento do VEF1 pós-broncodilatador ≥ 12%). A proporção de eosinófilos no escarro foi maior no grupo LFApr do que no LFAnr (p < 0,01), e houve uma correlação inversa entre a proporção de eosinófilos e VEF1 (p < 0,05). Entretanto, nenhum dos pacientes apresentou histórico de asma e os resultados dos testes cutâneos não diferiram entre os dois grupos. Nas amostras de escarro dos pacientes, os neutrófilos predominaram. Os níveis séricos de TNF, IL-6, IL-8 e RANTES (CCL5) foram maiores nos pacientes que nos controles (p < 0,001), mas não diferiram entre os dois grupos de pacientes.

CONCLUSÕES:: Pacientes com DPOC e reversibilidade parcial do VEF1 parecem apresentar maiores contagens de eosinófilos no escarro e maior hiper-responsividade das vias aéreas que aqueles sem reversibilidade do VEF1. Entretanto, a gravidade da DPOC não se correlacionou com atopia ou perfil das citocinas.

摘要

目的

确定慢性阻塞性肺疾病(COPD)的严重程度是否与痰液细胞计数、特应性和哮喘相关。

方法

这是一项横断面研究,纳入了37例COPD患者和22例肺功能正常的健康受试者(对照组)。样本经离心后通过显微镜检查确定痰液细胞计数。进行皮肤点刺试验,并通过酶联免疫吸附测定法(ELISA)测定血清细胞因子。

结果

根据支气管扩张剂反应对患者进行分层:不可逆气流受限(nonRAL)组包括24例患者,其第一秒用力呼气容积(FEV1)在支气管扩张剂使用后无显著变化;部分可逆气流受限(partialRAL)组包括13例患者,其FEV1具有可逆性(支气管扩张剂使用后FEV1增加≥12%)。partialRAL组痰液中嗜酸性粒细胞的比例高于nonRAL组(p<0.01),且嗜酸性粒细胞比例与FEV1呈负相关(p<0.05)。然而,所有患者均无哮喘病史,两组的皮肤点刺试验结果无差异。在患者痰液样本中,中性粒细胞占主导。患者血清中肿瘤坏死因子(TNF)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)和调节激活正常T细胞表达和分泌因子(RANTES,即CCL5)的水平高于对照组(p<0.001),但两组患者之间无差异。

结论

与FEV1无可逆性变化的COPD患者相比,FEV1部分可逆的COPD患者似乎痰液嗜酸性粒细胞计数更高,气道高反应性更强。然而,我们发现COPD的严重程度与特应性或细胞因子谱无关。

目的

确定慢性阻塞性肺疾病(COPD)的严重程度是否与痰液细胞计数、特应性和哮喘相关。

方法

这是一项横断面研究,纳入了37例COPD患者和22例肺功能正常的健康受试者(对照组)。样本经离心后通过显微镜检查确定痰液细胞计数。进行皮肤点刺试验,并通过酶联免疫吸附测定法(ELISA)测定血清细胞因子。

结果

根据支气管扩张剂反应对患者进行分层:不可逆气流受限(LFAnr)组包括24例患者,其第一秒用力呼气容积(VEF1)在支气管扩张剂使用后无显著变化;部分可逆气流受限(LFApr)组包括13例患者,其VEF1具有可逆性(支气管扩张剂使用后VEF1增加≥12%)。LFApr组痰液中嗜酸性粒细胞的比例高于LFAnr组(p<0.01),且嗜酸性粒细胞比例与VEF1呈负相关(p<0.05)。然而,所有患者均无哮喘病史,两组的皮肤点刺试验结果无差异。在患者痰液样本中,中性粒细胞占主导。患者血清中TNF、IL-6、IL-8和RANTES(CCL5)的水平高于对照组(p<0.001),但两组患者之间无差异。

结论

与VEF1无可逆性变化的COPD患者相比,VEF1部分可逆的COPD患者似乎痰液嗜酸性粒细胞计数更高,气道高反应性更强。然而,COPD的严重程度与特应性或细胞因子谱无关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1015/5063439/3deae5004d5c/1806-3713-jbpneu-42-04-00241-gf2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1015/5063439/f012f8b01207/1806-3713-jbpneu-42-04-00241-gf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1015/5063439/3deae5004d5c/1806-3713-jbpneu-42-04-00241-gf2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1015/5063439/f012f8b01207/1806-3713-jbpneu-42-04-00241-gf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1015/5063439/3deae5004d5c/1806-3713-jbpneu-42-04-00241-gf2.jpg

相似文献

1
Inflammatory and immunological profiles in patients with COPD: relationship with FEV 1 reversibility.慢性阻塞性肺疾病患者的炎症和免疫特征:与第1秒用力呼气容积可逆性的关系
J Bras Pneumol. 2016 Jul-Aug;42(4):241-247. doi: 10.1590/S1806-37562015000000122.
2
Evaluating bronchodilator response in pediatric patients with post-infectious bronchiolitis obliterans: use of different criteria for identifying airway reversibility.评估感染后细支气管炎闭塞症患儿的支气管扩张剂反应:不同标准在气道可逆性识别中的应用。
J Bras Pneumol. 2016 May-Jun;42(3):174-8. doi: 10.1590/S1806-37562015000000065.
3
Influence of heart failure on resting lung volumes in patients with COPD.心力衰竭对慢性阻塞性肺疾病患者静息肺容量的影响。
J Bras Pneumol. 2016 Jul-Aug;42(4):273-278. doi: 10.1590/S1806-37562015000000290.
4
Risk factors for cardiovascular disease in patients with COPD: mild-to-moderate COPD versus severe-to-very severe COPD.COPD 患者心血管疾病的风险因素:轻度至中度 COPD 与重度至极重度 COPD。
J Bras Pneumol. 2016 May-Jun;42(3):179-84. doi: 10.1590/S1806-37562015000000121.
5
Lung volumes and airway resistance in patients with a possible restrictive pattern on spirometry.肺量计检查可能存在限制性模式患者的肺容积和气道阻力。
J Bras Pneumol. 2016 Sep-Oct;42(5):341-347. doi: 10.1590/S1806-37562016000000091.
6
Staphylococcal superantigen-specific IgE antibodies: degree of sensitization and association with severity of asthma.葡萄球菌超抗原特异性IgE抗体:致敏程度及其与哮喘严重程度的关联
J Bras Pneumol. 2016 Sep-Oct;42(5):356-361. doi: 10.1590/S1806-37562016000000010.
7
Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study.茚达特罗与噻托溴铵对中度慢性阻塞性肺疾病患者运动耐量的影响:一项前瞻性随机交叉研究。
J Bras Pneumol. 2016 Sep-Oct;42(5):367-373. doi: 10.1590/S1806-37562015000000334.
8
Assessment of fatigue using the Identity-Consequence Fatigue Scale in patients with lung cancer.使用身份-后果疲劳量表对肺癌患者的疲劳状况进行评估。
J Bras Pneumol. 2017 May-Jun;43(3):169-175. doi: 10.1590/S1806-37562016000000033. Epub 2017 Jan 23.
9
Bronchodilator response cut-off points and FEV 0.75 reference values for spirometry in preschoolers.学龄前儿童肺量计检查中支气管扩张剂反应的临界点及第0.75秒用力呼气量(FEV₀.₇₅)参考值
J Bras Pneumol. 2016 Sep-Oct;42(5):326-332. doi: 10.1590/S1806-37562015000000216.
10
Blood Pressure Treatment Adherence and Control after Participation in the ReHOT.参与ReHOT后血压治疗的依从性与控制情况
Arq Bras Cardiol. 2016 Nov;107(5):437-445. doi: 10.5935/abc.20160165.

引用本文的文献

1
Bronchodilator reversibility and eosinophilic biomarkers in chronic obstructive pulmonary disease patients.慢性阻塞性肺疾病患者的支气管扩张剂可逆性和嗜酸性粒细胞生物标志物
Lung India. 2025 Mar 1;42(2):128-133. doi: 10.4103/lungindia.lungindia_261_24. Epub 2025 Feb 27.
2
Altered hypoxia-induced cellular responses and inflammatory profile in lung fibroblasts from COPD patients compared to control subjects.与对照组相比,慢性阻塞性肺疾病(COPD)患者肺成纤维细胞中缺氧诱导的细胞反应和炎症特征发生改变。
Respir Res. 2024 Jul 16;25(1):282. doi: 10.1186/s12931-024-02907-x.
3
Modulating asthma-COPD overlap responses with IL-17 inhibition.

本文引用的文献

1
Evaluation of atopy in patients with COPD.评估 COPD 患者的特应性。
J Bras Pneumol. 2013 May-Jun;39(3):296-305. doi: 10.1590/S1806-37132013000300006.
2
Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease.炎症生物标志物可改善慢性阻塞性肺疾病患者死亡的临床预测。
Am J Respir Crit Care Med. 2012 May 15;185(10):1065-72. doi: 10.1164/rccm.201110-1792OC. Epub 2012 Mar 15.
3
Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease.
抑制白介素-17 治疗哮喘-慢阻肺重叠(COPD)。
Front Immunol. 2023 Oct 27;14:1271342. doi: 10.3389/fimmu.2023.1271342. eCollection 2023.
4
Serum levels of biomarkers that may link chronic obstructive pulmonary disease and depressive disorder.可能与慢性阻塞性肺疾病和抑郁障碍相关的生物标志物的血清水平。
Pharmacol Rep. 2023 Dec;75(6):1619-1626. doi: 10.1007/s43440-023-00548-3. Epub 2023 Nov 3.
5
Peripheral Blood Eosinophils and Nine Years Mortality in COPD Patients.外周血嗜酸性粒细胞与 COPD 患者 9 年死亡率。
Int J Chron Obstruct Pulmon Dis. 2021 Apr 14;16:979-985. doi: 10.2147/COPD.S265275. eCollection 2021.
6
Combination of Systemic Inflammatory Biomarkers in Assessment of Chronic Obstructive Pulmonary Disease: Diagnostic Performance and Identification of Networks and Clusters.全身炎症生物标志物组合在慢性阻塞性肺疾病评估中的应用:诊断性能及网络与聚类分析
Diagnostics (Basel). 2020 Nov 30;10(12):1029. doi: 10.3390/diagnostics10121029.
7
Environmental fungal sensitisation associates with poorer clinical outcomes in COPD.环境真菌致敏与 COPD 的临床结局较差相关。
Eur Respir J. 2020 Aug 27;56(2). doi: 10.1183/13993003.00418-2020. Print 2020 Aug.
8
Bone marrow characterization in COPD: a multi-level network analysis.COPD 患者骨髓特征:多层次网络分析。
Respir Res. 2018 Jun 15;19(1):118. doi: 10.1186/s12931-018-0824-x.
9
Eosinophils in COPD: why should I care?慢性阻塞性肺疾病中的嗜酸性粒细胞:我为何要关注?
J Bras Pneumol. 2016 Jul-Aug;42(4):237-238. doi: 10.1590/S1806-37562016000400001.
慢性阻塞性肺疾病中的局部和全身细胞炎症及细胞因子释放。
Cytokine. 2011 Nov;56(2):298-304. doi: 10.1016/j.cyto.2011.07.010. Epub 2011 Aug 30.
4
Induced sputum and peripheral blood cell profile in chronic obstructive pulmonary disease.慢性阻塞性肺疾病中的诱导痰及外周血细胞谱
J Bras Pneumol. 2007 Sep-Oct;33(5):510-8. doi: 10.1590/s1806-37132007000500005.
5
It's time for an aetiology-based definition of chronic obstructive pulmonary disease.是时候对慢性阻塞性肺疾病进行基于病因学的定义了。
Respirology. 2007 May;12(3):317-9. doi: 10.1111/j.1440-1843.2007.01082.x.
6
[Diseases to differentiate from COPD, with emphasis on bronchial asthma].[需与慢性阻塞性肺疾病相鉴别的疾病,重点是支气管哮喘]
Nihon Rinsho. 2007 Apr;65(4):675-81.
7
Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.嗜酸性气道炎症与慢性阻塞性肺疾病急性加重:一项随机对照试验。
Eur Respir J. 2007 May;29(5):906-13. doi: 10.1183/09031936.00146306. Epub 2007 Feb 14.
8
Pulmonary biomarkers in chronic obstructive pulmonary disease.慢性阻塞性肺疾病中的肺生物标志物
Am J Respir Crit Care Med. 2006 Jul 1;174(1):6-14. doi: 10.1164/rccm.200510-1659PP. Epub 2006 Mar 23.
9
Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers.戒烟1年对慢性阻塞性肺疾病(COPD)患者及无症状吸烟者气道炎症的影响。
Eur Respir J. 2005 Nov;26(5):835-45. doi: 10.1183/09031936.05.00108904.
10
Relation between duration of smoking cessation and bronchial inflammation in COPD.慢性阻塞性肺疾病(COPD)患者戒烟持续时间与支气管炎症的关系
Thorax. 2006 Feb;61(2):115-21. doi: 10.1136/thx.2005.040519. Epub 2005 Jul 29.